Amphastar Pharmaceuticals Reports Q3 2025 Financial Results with Increased Revenues and Declining Net Income

Amphastar Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, revealing a slight increase in net revenues to $191.8 million, up from $191.2 million in the same period last year. Product revenues, which accounted for the majority of total revenues, rose to $191.8 million from $188.8 million, primarily driven by a 33% increase in sales of BAQSIMI®, which reached $53.6 million. However, the company experienced declines in sales of glucagon and epinephrine, which fell by 49% and 12%, respectively. The overall gross profit for the quarter was $98.6 million, representing a gross margin of 51%, down from 53% in the prior year.

In comparison to the previous fiscal period, Amphastar's operating expenses surged significantly, totaling $73.3 million, up from $44.9 million in Q3 2024. This increase was largely attributed to a $24.6 million litigation provision, which accounted for a substantial portion of the rise in general and administrative expenses. The company reported a net income of $17.4 million, or $0.37 per diluted share, a decrease from $40.4 million, or $0.78 per diluted share, in the same quarter last year.

Operationally, Amphastar has made strategic moves, including the launch of Iron Sucrose Injection in August 2025, which is expected to contribute to future revenues. The company also entered into a licensing agreement with Nanjing Anji Biotechnology Co., Ltd., which involves upfront payments and potential milestone payments totaling up to $42 million, along with royalties on net sales. As of September 30, 2025, Amphastar's total assets increased to $1.67 billion, up from $1.58 billion at the end of 2024, with cash and cash equivalents rising to $216.3 million.

The company reported a working capital increase of $73.9 million, reaching $434.2 million, and net cash provided by operating activities was $123.3 million for the nine months ended September 30, 2025. This was a decrease from $184.4 million in the same period last year, reflecting changes in operating assets and liabilities, particularly an increase in inventories and accounts receivable. Amphastar's total liabilities also rose to $889.5 million, compared to $845.2 million at the end of 2024.

Looking ahead, Amphastar anticipates continued fluctuations in sales due to competitive dynamics, particularly for glucagon and epinephrine products. The company plans to maintain its focus on expanding its product portfolio through research and development, with expectations of increased expenses in this area as it advances its pipeline of product candidates. The outlook remains cautiously optimistic, with the company relying on its cash reserves and operational cash flows to support future growth initiatives.